4.87
price up icon2.31%   0.11
after-market アフターアワーズ: 4.87
loading

Rezolute Inc (RZLT) 最新ニュース

pulisher
Jan 18, 2025

Rezolute, Inc. (NASDAQ:RZLT) Receives $24.13 Average Target Price from Analysts - Defense World

Jan 18, 2025
pulisher
Jan 15, 2025

Brokerages Set Rezolute, Inc. (NASDAQ:RZLT) Price Target at $24.13 - MarketBeat

Jan 15, 2025
pulisher
Jan 14, 2025

Rezolute shares Phase 2 clinical study update By Investing.com - Investing.com South Africa

Jan 14, 2025
pulisher
Jan 14, 2025

Rezolute shares Phase 2 clinical study update - Investing.com

Jan 14, 2025
pulisher
Jan 14, 2025

Rezolute Highlights Promising Phase 2 Ersodetug Results - TipRanks

Jan 14, 2025
pulisher
Jan 11, 2025

(RZLT) On The My Stocks Page - Stock Traders Daily

Jan 11, 2025
pulisher
Jan 08, 2025

Top 5 Small-cap Biotech Stocks (Updated January 2025) - Investing News Network

Jan 08, 2025
pulisher
Jan 08, 2025

Rezolute, Inc. (NASDAQ:RZLT) Shares Acquired by Geode Capital Management LLC - MarketBeat

Jan 08, 2025
pulisher
Jan 07, 2025

Rezolute Gains FDA Breakthrough Designation for Ersodetug - TipRanks

Jan 07, 2025
pulisher
Jan 07, 2025

Here's Why 'Trend' Investors Would Love Betting on Rezolute (RZLT) - Yahoo Finance

Jan 07, 2025
pulisher
Jan 07, 2025

FDA Grants Breakthrough Therapy Status to Rezolute's Ersodetug for Congenital Hyperinsulinism - StockTitan

Jan 07, 2025
pulisher
Jan 04, 2025

State Street Corp Acquires 13,000 Shares of Rezolute, Inc. (NASDAQ:RZLT) - Defense World

Jan 04, 2025
pulisher
Dec 28, 2024

MML Investors Services LLC Makes New $57,000 Investment in Rezolute, Inc. (NASDAQ:RZLT) - Defense World

Dec 28, 2024
pulisher
Dec 24, 2024

3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying - Yahoo Finance

Dec 24, 2024
pulisher
Dec 24, 2024

Brokerages Set Rezolute, Inc. (NASDAQ:RZLT) Target Price at $24.13 - Defense World

Dec 24, 2024
pulisher
Dec 21, 2024

Rezolute, Inc. (NASDAQ:RZLT) Given Average Rating of "Buy" by Analysts - MarketBeat

Dec 21, 2024
pulisher
Dec 19, 2024

Rezolute CFO Daron Evans buys $42,900 in company stock By Investing.com - Investing.com Australia

Dec 19, 2024
pulisher
Dec 18, 2024

Rezolute CFO Daron Evans buys $42,900 in company stock - Investing.com India

Dec 18, 2024
pulisher
Dec 18, 2024

Insider Buying: Rezolute, Inc. (NASDAQ:RZLT) CFO Buys 10,000 Shares of Stock - MarketBeat

Dec 18, 2024
pulisher
Dec 13, 2024

Rezolute's SWOT analysis: biotech stock's pipeline progress and market potential - Investing.com Nigeria

Dec 13, 2024
pulisher
Dec 13, 2024

Rezolute's SWOT analysis: biotech stock's pipeline progress and market potential By Investing.com - Investing.com South Africa

Dec 13, 2024
pulisher
Dec 13, 2024

Chief Financial Officer of Rezolute Daron Evans Buys 6.5% More Shares - Simply Wall St

Dec 13, 2024
pulisher
Dec 12, 2024

Rezolute (NASDAQ:RZLT) and BetterLife Pharma (OTCMKTS:PVOTF) Head to Head Comparison - Defense World

Dec 12, 2024
pulisher
Dec 11, 2024

When the Price of (RZLT) Talks, People Listen - Stock Traders Daily

Dec 11, 2024
pulisher
Dec 10, 2024

Rezolute expands authorized shares following shareholder approval - Investing.com

Dec 10, 2024
pulisher
Dec 10, 2024

Daron Evans, CFO of Rezolute, buys $53,166 in common shares By Investing.com - Investing.com Nigeria

Dec 10, 2024
pulisher
Dec 10, 2024

Daron Evans, CFO of Rezolute, buys $53,166 in common shares - Investing.com

Dec 10, 2024
pulisher
Dec 05, 2024

RZLT Stock Rises on FDA's Orphan Designation for Rare Disease Drug - MSN

Dec 05, 2024
pulisher
Dec 05, 2024

Rezolute Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Dec 05, 2024
pulisher
Dec 05, 2024

Rezolute Grants 150,000-Share Inducement Award to New Supply Chain Executive - StockTitan

Dec 05, 2024
pulisher
Dec 04, 2024

Rezolute retains steady stock target on Orphan Drug nod By Investing.com - Investing.com Canada

Dec 04, 2024
pulisher
Dec 04, 2024

RZLT Stock Rises On FDA's Orphan Designation For Rare Disease Drug - Barchart

Dec 04, 2024
pulisher
Dec 04, 2024

FDA Grants Orphan Drug Designation to Rezolute's Ersodetug for the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism - Marketscreener.com

Dec 04, 2024
pulisher
Dec 03, 2024

Rezolute: Ersodetug Downstream Tech Could Ignite The Hyperinsulinism Market (NASDAQ:RZLT) - Seeking Alpha

Dec 03, 2024
pulisher
Dec 03, 2024

Rezolute Receives Orphan-Drug Designation from FDA for Low Blood Sugar Treatment - MarketWatch

Dec 03, 2024
pulisher
Dec 03, 2024

FDA Grants Orphan Drug Designation to Rezolute's Ersodetug (RZ358) for the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism - The Manila Times

Dec 03, 2024
pulisher
Dec 03, 2024

Rezolute's Hypoglycemia Drug Wins FDA Orphan Drug Status; Phase 3 Trial Set for 2025 - StockTitan

Dec 03, 2024
pulisher
Nov 26, 2024

Rezolute, Inc. (NASDAQ:RZLT) Receives $24.13 Average Price Target from Analysts - MarketBeat

Nov 26, 2024
pulisher
Nov 25, 2024

Rezolute, Inc. Advances Late-Stage Trials for Rare Disease Therapies - TipRanks

Nov 25, 2024
pulisher
Nov 25, 2024

BTIG Initiates Coverage of Rezolute (RZLT) with Buy Recommendation - MSN

Nov 25, 2024
pulisher
Nov 23, 2024

Rezolute, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended June 30, 2024 - Marketscreener.com

Nov 23, 2024
pulisher
Nov 21, 2024

Wedbush Initiates Coverage of Rezolute (RZLT) with Outperform Recommendation - MSN

Nov 21, 2024
pulisher
Nov 18, 2024

Institutional investors in Rezolute, Inc. (NASDAQ:RZLT) lost 11% last week but have reaped the benefits of longer-term growth - Simply Wall St

Nov 18, 2024
pulisher
Nov 16, 2024

Is Rezolute, Inc. (RZLT) the Best Multibagger Stock to Buy Heading into 2025? - Insider Monkey

Nov 16, 2024
$30.75
price down icon 0.65%
$71.93
price down icon 0.75%
$19.03
price up icon 4.62%
$358.93
price down icon 2.04%
biotechnology ONC
$210.08
price up icon 2.31%
$111.93
price down icon 0.74%
大文字化:     |  ボリューム (24 時間):